629 related articles for article (PubMed ID: 15530129)
1. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
3. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
5. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
6. "Weak" opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine.
Prescrire Int; 2016 Feb; 25(168):45-50. PubMed ID: 27042732
[TBL] [Abstract][Full Text] [Related]
7. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?
Lötsch J; Zimmermann M; Darimont J; Marx C; Dudziak R; Skarke C; Geisslinger G
Anesthesiology; 2002 Oct; 97(4):814-9. PubMed ID: 12357145
[TBL] [Abstract][Full Text] [Related]
8. Reviewing pharmacogenetics to advance precision medicine for opioids.
Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of opioid response.
Somogyi AA; Coller JK; Barratt DT
Clin Pharmacol Ther; 2015 Feb; 97(2):125-7. PubMed ID: 25670515
[TBL] [Abstract][Full Text] [Related]
10. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
11. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
12. [Interaction of opioid analgesics at the level of biotransformation].
Petri H; Grandt D
Schmerz; 2016 Dec; 30(6):519-525. PubMed ID: 27439327
[TBL] [Abstract][Full Text] [Related]
13. Trends in Tramadol: Pharmacology, Metabolism, and Misuse.
Miotto K; Cho AK; Khalil MA; Blanco K; Sasaki JD; Rawson R
Anesth Analg; 2017 Jan; 124(1):44-51. PubMed ID: 27861439
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of opioids.
Somogyi AA; Barratt DT; Coller JK
Clin Pharmacol Ther; 2007 Mar; 81(3):429-44. PubMed ID: 17339873
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
17. Opioid pharmacokinetic drug-drug interactions.
Overholser BR; Foster DR
Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
Eissing T; Lippert J; Willmann S
Mol Diagn Ther; 2012 Feb; 16(1):43-53. PubMed ID: 22352453
[TBL] [Abstract][Full Text] [Related]
19. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.
Mikus G; Bochner F; Eichelbaum M; Horak P; Somogyi AA; Spector S
J Pharmacol Exp Ther; 1994 Feb; 268(2):546-51. PubMed ID: 8113966
[TBL] [Abstract][Full Text] [Related]
20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
